Funding boost gets Sunho Biologics over the IPO filing line
The cash-burning biotech has applied to list on the Hong Kong Stock Exchange after only barely achieving the minimum market value Key Takeaways: With no product or licensing revenue, Sunho…
Recent Articles
RECENT ARTICLES
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK - Cancer drug maker Genfleet joins Hong Kong IPO influx
- Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
-
Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
688062.SHG
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
